TITLE

US to introduce strategy to confront prescription drug abuse

PUB. DATE
March 2004
SOURCE
Reactions Weekly;3/13/2004, Issue 992, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the National Drug Control Strategy announced by the U.S. government, in association with the U.S. Food and Drug Administration and Drug Enforcement Agency in March 2004. Aim of the program to combat the prevalence of prescription drug abuse in the country; Increase in the abuse of opioid pain killers in the country during the last 10 years; Details of programs included in the strategy.
ACCESSION #
16062199

 

Related Articles

  • Targeting Prescription Drug Abuse--A New Federal Initiative. Taylor, Trusandra // Behavioral Health Management;Jul/Aug2004, Vol. 24 Issue 4, p37 

    Presents information on the initiative of the U.S. federal government with regard to prescription drug abuse. Prevalence of nonmedical use of prescription drugs among youth and young adults; Increase in emergency room visits associated with opioid pain relievers; Investigation and law...

  • ANNOUNCEMENT.  // Touching Base;2016, Vol. 9 Issue 11, p2 

    The article focuses on a joint project undertaken by the Drug Enforcement Administration (DEA) and discovery education called "Operation Prevention" to educate school students about the impact of prescription opioid misuse and heroin use.

  • Manufacturers Under Pressure to Manage Painkillers. Wechsler, Jill // Pharmaceutical Technology Europe;Apr2013, Vol. 25 Issue 4, p18 

    The article discusses the U.S. regulation and production of painkiller medicines which are subjected to drug abuse. According to the Centers for Disease Control and Prevention (CDC), more than 16,500 died in 2010 because of abuse and misuse of painkiller drugs. It says that U.S. Food and Drug...

  • New rules for opioid prescribing. Elliott, William T. // Infectious Disease Alert;Apr2009 Pharmacology, p2 

    The article reports on the plans of the U.S. Food and Drug Administration (FDA) to issue new restrictions for opioid prescribing in 2009. Under the rules, opioid makers will be required to have a Risk Evaluation and Mitigation Strategy. Opioids included in the rules include fentanyl,...

  • Opioid Regulation Challenges FDA and Manufacturers. Wechsler, Jill // BioPharm International;Dec2013, Vol. 26 Issue 12, p12 

    The article focuses on the challenges faced by the U.S. Food and Drug Administration (FDA) and manufacturers over the regulation on opioids. The increase in misuse of long-acting opioids has led to efforts to formulate safer therapies for patients suffering from pain while also taking steps to...

  • How to safely prescribe long-acting opioids. Gregory, Thomas B. // Journal of Family Practice;Dec2013, Vol. 62 Issue 12, pS12 

    The article discusses safe prescription of long-acting opioids. It mentions the Drug Abuse Warning Network statistics which shows that 1.3 million of 4.9 million drug-related emergency department (ED) visits in 2010 were for abuse or misuse of pharmaceuticals. It says that the U.S. Food and Drug...

  • Update on Risk Evaluation and Mitigation Strategies (REMS) associated with long-acting opioids. Fudin, Jeffrey // Drug Topics;Oct2011, Vol. 155 Issue 10, p45 

    The article offers an update on the Risk Evaluation and Mitigation Strategies (REMS) program to reduce the risk and prevalence of opioid abuse in the U.S. which was instituted by the U.S. Food and Drug Administration. The author states that with the REMS and other collaborative practices, a...

  • FDA Opioid Safety Plan Promotes Patient, Physician Education to Prevent Abuse. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;8/25/2010, Vol. 304 Issue 8, p845 

    The article reports on a proposal from the U.S. Food and Drug Administration (FDA) aimed at preventing overdoses of long-acting and extended-release opioid medications. Under the proposal, drug makers will be required to provide voluntary clinician and patient safety education despite the...

  • Technology: Barriers to misuse. Dolgin, Elie // Nature;6/25/2015 Supplement, Vol. 522 Issue s7557, pS60 

    The article discusses the science and manufacturing of misuse-deterrence in the U.S. Topics covered include the concern of manufacturers on prescription-drug misuse, painkillers that have Food and Drug Administration (FDA)-approved misuse-deterrent labelling, and the role of regulations on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics